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Biological markers are necessary for predicting prognosis of salivary malignancies and better understanding the pathogenesis of
salivary cancer. We analysed terminal deoxynucleotidyl transferase (TdT)-mediated biotinylated deoxyuridine-triphosphate (dUTP)-
biotin nick-end labelling (TUNEL), p53 and Ki67 expression in 66 patients with malignant salivary tumours by immonohistochemistry,
and correlated the data with survival, disease-free survival, tumour grade, stage, and local and distant metastasis. TUNEL efficiently
predicted poor prognosis in salivary malignancies. The 5-year (5Y) survival probability dropped significantly with the level of TUNEL
staining (from 83% in negatively stained tumours to 57 and 24% in TUNEL positively stained levels 1 and 2, respectively), (P¼0.042).
Extensive Ki67 staining (in addition to TUNEL) reduced the 5Y-survival rate even further and addition of positively stained p53
dropped the 5Y-survival rate to 0. The correlation rates between TUNEL and Ki67 was 58% (P¼0.0001), and between TUNEL and
p53 it was 50% (P¼0.035). Concurrently, TUNEL correlated with metastasis, extracapsular spread, grade and stage. The correlation
between TUNEL, p53 and Ki67 staining and survival probabilities, and the pathological grade, stage and metastasis spread of salivary
malignancies makes this a highly effective tool in patient follow-up and prognosis.
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Salivary gland tumours are rare tumours of the head and neck
region (Eneroth, 1971; Eveson and Cawson, 1985). The diagnosis
and treatment of these tumours represent a challenge for head
and neck surgeons for several reasons: they occur relatively
infrequently, are found in diverse sites and show a great deal of
variation in histological characteristics, clinical appearance,
pathogenesis and 5-year (5Y) survival probability (Spiro and
Dubner, 1990). These tumours may arise within the major salivary
glands (parotid, submandibular (Sm) and sublingual (Sl)) or in
one of the 600–1000 minor salivary glands spread throughout the
oral mucosa (Johns and Goldsmith, 1989a). Their morphologic
diversity and relative rarity frequently make it difficult to perform
comparative analysis of their biologic, pathologic and clinical
characteristics, which could facilitate estimating prognosis and
establishing a preferable therapeutic modality (Batsakis, 1980;
Dardick and van Nostrand, 1987; Batsakis et al, 1989; Johns and
Goldsmith, 1989b; Dardick, 1991).
It is generally recognised that the prognosis of patients with
salivary gland tumours depends basically on the salivary gland and
the site in which they occur, the histological type, the extension of
the disease at the time of diagnosis and the completeness of the
surgical resection and/or radiotherapy administered (Eveson and
Cawson, 1985; O’Brien et al, 1986; Tran et al, 1986; Hermanek et al,
1997; Batsakis, 1999). It is also known that salivary gland tumours
have diverse outcomes: some patients are considered ‘cured’
decades after surgery, whereas others experience early recurrence
and some die of the disease. As the clinical course and final
outcome of many patients with salivary gland tumours cannot be
reliably predicted on the basis of pathological histomorphologic
features, it is highly desirable to pinpoint new prognosis markers
aimed at better characterizing tumour aggressiveness and identify-
ing especially subgroups of patients at the highest risk of
recurrence who would benefit from adjuvant therapy. It is
reasonable to assume that further improvement of the survival
rate may be related to a better understanding of the biological
nature of the disease, which in turn may facilitate the development
of more efficient tools for the detection and treatment of these
tumours. A significant effort has been made in finding valuable
tumour markers for salivary-gland cancer in the last decade
(Nagler et al, 1999).
In the current study, immunohistological examination of the
following tumour markers were performed: the apoptosis regula-
tory terminal deoxynucleotidyl transferase (TdT)-mediated
biotinylated deoxyuridine-triphosphate (dUTP)-biotin nick-end
labelling (TUNEL) technique (for apoptosis rate assessment) and
the carcinogenesis vs apoptosis-related p53 and the cell prolifera-
tion-rate-marker Ki67. We determined the percentage of apoptotic
cells labelled by the well-established TUNEL method, which
enables the visualization of apoptotic cells using an in situ end-
labelling technique that labels DNA breaks in apoptotic cells (Ben-
Sasson et al, 1995). Mutation in the p53 gene, which results in
encoded non-functional protein is considered as the most common
genetic event in human cancer. It has been suggested that mutated
p53 may lead to carcinogenesis, as the wild-type p53 contributes to
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stumour suppression through at least two mechanisms in response
to DNA damage, arrest of cell proliferation and induction of
apoptosis (Attardi et al, 1996; Ravi et al, 1999; Xie et al, 1999).
It is unfortunate that only limited research has been devoted to
examining these markers in salivary tumours, and that the TUNEL
method has been only scarcely utilised. Moreover, all these
markers have never been examined concomitantly or in relation
to other clinical carcinogenic characteristics and in various types
of malignant salivary tumours. In any case, given the mentioned
variability and complexity of these tumours, a better under-
standing of their basic biology is required to define relevant targets
for the development of novel therapeutic approaches. Thus, the
purpose of the current study was to analyse all these and, in a
relatively large cohort of patients, to correlate the obtained data
with the survival and disease-free-survival (DFS) rates, and with
other currently available clinical tools for prognosis prediction.
MATERIALS AND METHODS
Patients and experimental design
A total of 66 patients with a mean age of 60716 years (range of
15–90 years) and a gender distribution of 41 (62%) males and 25
(38%) females who were diagnosed with various malignant salivary
tumours were enrolled in the current study. Data concerning
clinical tumour characteristics were collected and analysed: type of
tumour, salivary gland involved (parotid, Sm, Sl or minor salivary
glands), stage of disease, size (T), neck metastasis (N), distant
metastasis (M) and the existence/absence of extracapsular spread
of these neck metastases. The level of TUNEL staining of the
tumours was correlated with all these clinical data as well as with
patient survival and DFS probabilities. TUNEL-staining rate was
also correlated with the staining rates of p53 and Ki67.
Pathological study
All specimens were formalin-fixed and paraffin-embedded follow-
ing surgical harvesting. Shortly before the immunological evalua-
tion, serial sections (4mm in thickness) were prepared for
haematoxylin and eosin staining, p53 and Ki67 immunostaining
and for the TUNEL staining.
TUNEL staining
Sections were stained by the in situ death-detection POD kit
(Roche Diagnostic GmbH, Mannheim, Germany), according to the
manufacturer’s instructions. Briefly, after deparaffinisation and
rehydration, sections were incubated with proteinase K
(20mmml
 1 in 10mM Tris–HCL, pH 7.4) for 30min at 371C.
Slides were rinsed with PBS and incubated with 3% H2O2 in
methanol for 10min at room temperature to block endogenous
peroxidase activity, followed by PBS washing and incubation in
0.1% Triton X-100 in 0.1% sodium citrate for 2min on ice (41C).
Sections were incubated with a mixture of TdT solution and
fluorescein isothiocyanate dUTP solution in a humidified chamber
at 371C for 60min. This was followed by washings with PBS and
incubation with antifluorescein antibody Fab fragments conju-
gated with horseradish peroxidase in a humidified chamber at
371C for 30min. After washing with PBS, aminoethyl carbazole
solution was applied, followed by light counterstain with
haematoxylin. Paraffin-embedded sections of normal tonsils were
used as positive control. Negative control was obtained by
replacing the TdT solution with distilled water. The presence of
clear nuclear staining was indicative of apoptotic cells. At least
1000 tumour cell nuclei were examined in the most evenly and
distinctly labelled areas. The number of TUNEL-positive tumour
cell nuclei was counted and the apoptotic index was the percentage
of apoptotic cells in the tumour. The apoptotic indices were
classified into three groups: 3% (2).
P53 and Ki67 staining
Four-micrometre paraffin-embedded sections were dewaxed and
rehydrated. Endogenous peroxidase was blocked by incubation
with 3% H2O2 in methanol for 10min. Nonspecific binding was
blocked by incubation in 10% normal serum for 20min. Sections
were heated in a microwave oven at 800W for 15min in 10mM
citrate buffer, pH 6. The primary antibodies used in the Ki67 study
were anti-Ki67, clone MIB-1, diluted 1:40 (Zymed Laboratories.
San Francisco, CA, USA). The antibodies used in the p53 study
were anti-p53 (clone BP 53.12; 1:100, from Zymed Laboratories).
Slides were incubated with the antibodies and antiserum for
60min at room temperature, followed by the application of the
streptavidin–biotin complex method (histostain plus; Zymed
Laboratories). Colour development was performed with amino-
ethyl cabazole followed by light haematoxylin counterstaining.
Positive controls were run in parallel: colonic tumour, known to
show strong p53, at least 500 tumour cells were counted in the
areas with strongest staining. Positive staining for Ki67 was
defined as level 1 (1–19%), level 2 (20–39%) or level 3 (40–60%).
Positive staining for p53 was considered when more than 10% of
tumour cells showed strong nuclear staining: staining of 10–30%
of cells was classified as þ1; and staining of 430% of cells was
classified as þ2.
Statistical analysis
For categorical variables, frequencies and percentages were
calculated. Distributions for categorical variables were compared
and analysed by the Fisher–Irwin exact test (small sample). The
Kaplan–Meier estimate was used to calculate the probability of
survival and DFS rates as a function of time. The log rank test was
used to compare the survival curves. The correlations between
pairs of parameters were analysed by Pearson’s correlation.
RESULTS
Tumour characteristics and survival rates
The 66 analysed malignant tumours included the following
subgoups: mucoepidermoid (n¼15), adeno carcinoma (n¼12),
squamous cell carcinoma (n¼10), acinic cell carcinoma (n¼9),
adenoid cystic carcinoma (n¼6), polymorphous low-grade adeno
carcinoma (n¼5), carcinoma ex mix tumour (n¼2), salivary duct
and neuroendocrine carcinoma (one from each) and undefined
tumours (n¼5). The distribution of TUNEL-staining level
types was not statistically different among the various salivary
malignancy subgroups.
The 5Y survival rate dropped with larger T, N, M and stage
values. For T¼1, 5Y survival was 70%, but dropped to 25% for
T¼3–4 (P¼0.038). For N¼0, 5Y survival was 53% but for any
positive N the survival rate dropped to 0 (P¼0.01). Similarly, for
any positive M, survival rate dropped to 0 (P¼0.16). For stage 1
patients, the 5Y survival rate was 70%, and for patients in
advanced stages (3–4) it dropped to 20–26% (P¼0.05).
Most of the tumours were located in the parotid gland (n¼38,
55%), whereas in the Sm, Sl and minor salivary glands there were
seven, two and 19 cases in each. Of the 19 minor salivary tumours,
12 were located in the palate and seven were located in other sites
of the oral mucosa. Post surgical margins were healthy and remote
from the tumour by at least 1cm in all cases. The distribution
of the tumours among the various salivary glands was not
significantly different, nor was the distribution of TUNEL staining
levels in each of the salivary glands. The distribution scale of
malignant lesions according to size (T) was up to 2cm (T1),
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s2–4cm (T2), 4–6cm (T3) and 46cm (T4), Most of the tumours
(67%) were T1–T2 tumours. Although 15% (9/56) had neck
metastasis (N1¼4, N2¼5), only 5% of the patients (3/56) had
distant metastasis (positive M) (Table 1).
Tumour markers
The immunohistochemical analysis demonstrated positive staining
for TUNEL in 52% of the salivary tumours analysed. These were
composed of 35% moderately stained tumours (level 1) and 17%
profoundly stained tumours (level 2). There was no significant
difference among the levels of TUNEL staining according to either
the specific type of salivary tumour involved or salivary gland
involved.
Positive staining for p53 was found in 38% of the tumours (28%
were stained with level 1 and 10% with level 2), whereas those
stained with Ki67 revealed the following rates: 75% of all tumours
for level 1 (1–19%), 17% for level 2 (20–39%) and 8% for level 3
(40–60%). All healthy tissues surrounding the tumours were not
stained positively for any of these markers.
The correlation rates between TUNEL and Ki67 was 58%
(P¼0.0001) and between TUNEL and p53 it was 50% (P¼0.035).
The correlation rate between TUNEL and n values was rather high
(R¼0.50, P¼0.0002), (Table 2). The level of TUNEL staining also
correlated with the histopathological grading of the tumour
(P¼0.017), (Table 1). As can be seen in Table 3, the 5Y survival
frequency dropped significantly to 17% in tumours where TUNEL
and Ki67 were concomitantly positively stained (n¼12, P¼0.005)
and when p53 also stained positively (n¼3) the 5Y survival
frequency dropped to 0.
TUNEL staining and neck metastasis (N values)
The level of the TUNEL staining grew larger with the N-positive
rate (as demonstrated by clinical palpation of the neck),
(P¼0.014). Interestingly, similar high correlation rate was found
between TUNEL staining level and positive neck metastasis as
defined by the pathological analysis (post-operative) (P¼0.011),
but not as defined by the preoperative CT imaging (P¼0.54).
Moreover, TUNEL-staining level was also found to indicate an
extracapsular spread from the neck metastasis (a lethal pheno-
menon) as can be seen in Table 1.
TUNEL staining and survival rates
According to the age-adjusted Kaplan–Meier analysis performed,
the survival and DFS probability rates dropped with the TUNEL
level of staining (Figures 1–3). Thus, although the 5 and 10 years
Table 1 Distribution of TUNEL levels by grade, T, N and extracapsular
spread
TUNEL level
0 patients
(%)
One patient
(%)
Two patients
(%)
(A) Grade level
Low (n¼10) 8 (62) 2 (17)
Intermediate (n¼8) 2 (15) 4 (33) 2 (22)
High (n¼16) 3 (23) 6 (50) 7 (78)
Total (n¼34) 13 (100) 12 (100) 9 (100)
(B) T level
1( n¼20) 12 (41) 7 (41) 1 (10)
2( n¼24) 12 (41) 7 (41) 5 (50)
3( n¼4) 1 (4) 3 (30)
4( n¼8) 4 (14) 3 (18) 1 (10)
Total (n¼56) 29 (100) 17 (100) 27 (100)
(C) N level
0( n¼47) 28 (97) 13 (76) 6 (60)
1( n¼4) 1 (3) 2 (12) 1 (10)
2( n¼5) 2 (12) 3 (30)
Total (n¼56) 29 (100) 17 (100) 10 (100)
(D) Neck extracapsular spread
No 13 (100) 4 (80) 4 (80)
Yes — 1 (20) 1 (20)
Total (n¼23) 13 (100) 5 (100) 5 (100)
N¼neck metastasis; T¼size; TUNEL¼terminal deoxynucleotidyl transferase-
mediated biotinylated deoxyuridine-triphosphate biotin nick-end labelling. Exact test:
P¼0.017 significant. Exact test: P¼0.14. Exact test: P¼0.014. P¼0.05.
Table 2 Correlation factor between TUNEL level of staining and T, N,
M and stage values
Correlation factor between TUNEL
Stage r¼0.25
(P¼0.08)
T r¼0.16
(P¼0.23)
N r¼0.50
(P¼0.0002)
M r¼0.12
(P¼0.40)
M¼distant metastasis; N¼neck metastasis; T¼size; TUNEL¼terminal deoxynu-
cleotidyl transferase-mediated biotinylated deoxyuridine-triphosphate biotin nick-end
labelling.
Table 3 5Y survival frequency by concomitant TUNEL, Ki67 and p53
staining levels (0 staining depicts negative staining for all marker/s
analysed, 40 staining depicts positive staining for all marker/s analysed)
(A) TUNEL and Ki67
5Y survival
patients
5Y survival
patients (%)
0( n¼28) 19/28 68
40( n¼12) 2/12 17
Total (n¼40) 21/40
(B) TUNEL, Ki67 and p53
0( n¼10) 10/10 100
40( n¼3) 0/3 0
Total (n¼13) 10/13
TUNEL¼terminal deoxynucleotidyl transferase-mediated biotinylated deoxy-
uridine-triphosphate biotin nick-end labelling; 5Y¼5 year. Exact test: P¼0.005
significant. Exact test: P¼0.003 significant.
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Figure 1 Survival probability curves of salivary-gland tumour patients
according to TUNEL immunostaining levels. Kaplan–Meier analysis (age-
adjusted) showed poor survival in patients with positive TUNEL
expression. Follow-up of 120 months showed 24% survival of TUNEL –
level 2-positive patients compared with 66% survival of patients with no
detectable TUNEL expression. (P¼0.042).
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sof survival rates for negative TUNEL staining (¼0) were 83 and
66%, respectively, these values dropped for positive TUNEL
staining. When the staining level¼1, they dropped to 57 and
50%, respectively, and when the staining level¼2, they both
dropped to 24% (P¼0.042). Similarly, the DFS rates for negative
TUNEL staining (¼0) at 5 and 10 years were 78 and 50%,
respectively, but these, too, dropped for positive TUNEL staining.
When the staining level¼1, they dropped to 54 and 25%,
respectively, and when the staining level¼2, they both dropped
to 23% (P¼0.05).
DISCUSSION
TUNEL was found to be a most powerful marker for predicting
poor prognosis in salivary malignancies. Concurrently it correlated
with the most important clinical characteristics currently used for
prognosis predicting histopathological grade, metastasis spread,
extra-capsular spread and stage. Moreover, TUNEL was also found
to correlate positively with the staining of both p53 and Ki67,
which are considered the most established markers of carcino-
genesis and proliferation (in spite of the fact that our currently
employed IHC analysis of p53 may not fully reflect the mutational
status of this gene). Most interestingly, these clinical and
histopathological markers also correlated with each other, giving
the results further credence. This is the first time that such findings
are concomitantly demonstrated in salivary malignancies. Owing
to the well-known diversity among various malignancies in
salivary glands it is often impossible to draw significant
conclusions from an analysis of a limited number of tumours or
from only one type of tumour. Accordingly, we chose to study a
relatively large number of salivary tumours (n¼66) including
different types in one cohort, using their associated survival and
DFS probabilities as the most important clinical end points. These
were correlated with both clinical characteristics and histopatho-
logical markers mentioned previously.
Apart form the obvious clinical significance of finding TUNEL
to be a powerful predictor for recurrences and poor survival in
salivary malignancies, the concomitant positive staining of
TUNEL, p53 and Ki67 may shed further light on the carcinogenetic
pathogenesis of salivary malignancies.
Our results are supported by previous studies in which the
frequency of apoptosis in salivary malignant tumours was
reportedly higher than in benign tumours (Nagao et al, 1998;
Soini et al, 1998), and by another study reporting that a higher
apoptosis index was assessed by the TUNEL method in the solid
pattern of adenoid cystic carcinoma than in the glandular pattern
(the solid-pattern carcinoma is known to have a poorer prognosis)
(Fujita et al, 1999). In this regard, it is interesting to note that
previous studies found the level of positive TUNEL staining to be
relatively high not only in salivary glands malignancies but also in
oral cancer (Loro et al, 1999; Nagler et al, 1999,2003). Our results
are also supported by multiple recent studies of various non-
salivary malignancies which demonstrated that high scores of Ki67
and p53 staining predict a higher tumourogenic grade, a higher
rate of metastasis spread and a poorer prognosis, whereas low
scores of Ki67 and p53 are associated with prognostically better
histopathologic features (Saleh et al, 2000; Ben-Izhak et al, 2001,
2002, 2003; Jalava et al, 2006). Furthermore, in gastric cancer
significant relationships between TUNEL, Ki67 and grade have
been reported (Jesionek-Kupnicka et al, 2002), whereas in oral
leukoplakia higher levels of TUNEL, Ki67 and p53 have been
reported, indicating increased instability of the genome and higher
severity of the dysplasia and the clinical stage (Kovesi and Szende,
2004). Ki67 and p53 were strongly expressed in high-grade prostate
cancer tumours (Szabo et al, 2000), and higher grade breast
carcinoma tumours have been reported as characterised by higher
levels of p53 and TUNEL staining (Gonzalez-Campora et al, 2000).
Bladder cancer grade, p53, Ki67, TUNEL and poor survival
have been positively correlated (Shiina et al, 1999) and similar
results have been found for both non-Hodgkin’s lymphoma.
(Korkolopoulou et al, 1998) and adrenocortical carcinoma
(Khoury et al, 2003).
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Figure 2 DFS probability curves of salivary-gland tumour patients
according to TUNEL expression levels. Kaplan–Meier analysis (age-
adjusted) showed significantly poorer DFS in patients with positive TUNEL
staining than those with negative (0) TUNEL expression. Follow-up of 120
months (10 years) showed 23% survival of level 2-positive TUNEL-staining
patients, compared with 78% survival of patients with negative staining
(P¼0.05).
A
B
Figure 3 Immunohistochemical staining of TUNEL in patients with
salivary malignant tumours. Formalin-fixed, paraffin-embedded mm
sections of salivary gland tumours were subjected to immunostaining of
TUNEL. Representative photomicrographs of negative (A) acinic cell
carcinoma and positive (B) mucoepidermoid TUNEL staining are
presented.
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sWe currently employed TUNEL staining in salivary tumours for
evaluation of their malignant profile as TUNEL examination has
often been performed by investigators in other cancer types and in
view of the fact that an unbalanced admixture of proliferative cells
and apoptotic cells in neoplastic parenchyma is related to tumour
growth. When the growth features of tumours are discussed, not
only cell proliferation but also cell death, especially apoptosis,
should be taken into consideration. However, TUNEL in situ
technique for the detection of apoptosis is not completely specific,
as overlap between apoptotic and necrotic cell death has been
reported, which may result in the fact that some of the apoptotic
cells do not stain (Finlay et al, 1988; Wyllie et al, 1999). TUNEL
evaluation and scoring is a difficult task for clinical application.
Early DNA fragmentation may not be readily detected by the
TUNEL assay and this may lead to underestimation of the
apoptotic values. Moreover, the margin of error in scoring TUNEL
between cases is too narrow to allow for definitive categorization.
The report of Grasl-Kraupp et al (1995), which found that
TUNEL failed to distinguish between apoptotic and necrotic cells,
strengthens this point. Thus, the exact biological pathway
expressed by the positive TUNEL staining is yet to be fully
elucidated and its exploration is highly warranted. This may lead
to finding a cellular target (associated or non-associated with p53
and/or Ki67), which might be used for anti-carcinogenetic therapy.
Finally, it is noteworthy to mention a paper published recently by
Jalava et al (2006), which seems to show that mitotic activity and
apoptotic activity are related in breast cancer and that Ki-67 may
not be the best possible proliferation-associated prognosticator but
rather the mitotic count. Furthermore, in 2000 this group (Jalava
et al, 2000) showed that Bcl-2 immunostaining could potentially
replace TUNEL as its prognostic value is well-established in breast
cancer.
In summary, the demonstrated significant concurrent staining
of salivary malignant tumours for TUNEL, p53 and Ki67 indicates
a biological role of all three markers in the pathogenesis of salivary
malignancies. The significant correlation between TUNEL staining
and the survival and DFS rates and the histopathological grade,
stage and metastasis spread of these malignancies is of paramount
importance for both prognostic as well as follow-up purposes.
Further analysis of these markers role in the pathogenesis of
specific salivary malignancies is warranted in the future, being
based on larger cohorts of the tumours.
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